Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds.

Guerrero-Juarez CF, Dedhia PH, Jin S, Ruiz-Vega R, Ma D, Liu Y, Yamaga K, Shestova O, Gay DL, Yang Z, Kessenbrock K, Nie Q, Pear WS, Cotsarelis G, Plikus MV.

Nat Commun. 2019 Feb 8;10(1):650. doi: 10.1038/s41467-018-08247-x.

2.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

3.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.

Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31.

4.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

5.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

6.

Improved surfaceome coverage with a label-free nonaffinity-purified workflow.

Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R, Seeholzer SH.

Proteomics. 2017 Apr;17(7). doi: 10.1002/pmic.201600344. Epub 2017 Mar 6.

7.

High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.

Chiang MY, Wang Q, Gormley AC, Stein SJ, Xu L, Shestova O, Aster JC, Pear WS.

Blood. 2016 Nov 3;128(18):2229-2240. Epub 2016 Sep 26.

8.

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28. No abstract available.

PMID:
27677739
9.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.

10.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

11.

Off-Target V(D)J Recombination Drives Lymphomagenesis and Is Escalated by Loss of the Rag2 C Terminus.

Mijušković M, Chou YF, Gigi V, Lindsay CR, Shestova O, Lewis SM, Roth DB.

Cell Rep. 2015 Sep 22;12(11):1842-52. doi: 10.1016/j.celrep.2015.08.034. Epub 2015 Sep 10.

12.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.

Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.

13.

RAG2 mutants alter DSB repair pathway choice in vivo and illuminate the nature of 'alternative NHEJ'.

Gigi V, Lewis S, Shestova O, Mijušković M, Deriano L, Meng W, Luning Prak ET, Roth DB.

Nucleic Acids Res. 2014 Jun;42(10):6352-64. doi: 10.1093/nar/gku295. Epub 2014 Apr 20.

14.

The Notch1 transcriptional activation domain is required for development and reveals a novel role for Notch1 signaling in fetal hematopoietic stem cells.

Gerhardt DM, Pajcini KV, D'altri T, Tu L, Jain R, Xu L, Chen MJ, Rentschler S, Shestova O, Wertheim GB, Tobias JW, Kluk M, Wood AW, Aster JC, Gimotty PA, Epstein JA, Speck N, Bigas A, Pear WS.

Genes Dev. 2014 Mar 15;28(6):576-93. doi: 10.1101/gad.227496.113.

15.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.

Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. Erratum in: Blood. 2016 Nov 24;128(21):2585.

16.

Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells.

Chiang MY, Shestova O, Xu L, Aster JC, Pear WS.

Blood. 2013 Feb 7;121(6):905-17. doi: 10.1182/blood-2012-03-416503. Epub 2012 Oct 31.

17.

A critical role for TCF-1 in T-lineage specification and differentiation.

Weber BN, Chi AW, Chavez A, Yashiro-Ohtani Y, Yang Q, Shestova O, Bhandoola A.

Nature. 2011 Aug 3;476(7358):63-8. doi: 10.1038/nature10279.

18.

Identification of Flt3⁺CD150⁻ myeloid progenitors in adult mouse bone marrow that harbor T lymphoid developmental potential.

Chi AW, Chavez A, Xu L, Weber BN, Shestova O, Schaffer A, Wertheim G, Pear WS, Izon D, Bhandoola A.

Blood. 2011 Sep 8;118(10):2723-32. doi: 10.1182/blood-2010-09-309989. Epub 2011 Jul 26.

19.

Notch dimerization is required for leukemogenesis and T-cell development.

Liu H, Chi AW, Arnett KL, Chiang MY, Xu L, Shestova O, Wang H, Li YM, Bhandoola A, Aster JC, Blacklow SC, Pear WS.

Genes Dev. 2010 Nov 1;24(21):2395-407. doi: 10.1101/gad.1975210. Epub 2010 Oct 8.

20.

Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding.

Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, Toscano K, Uljon SN, Blacklow SC, Pear WS.

Blood. 2010 Dec 2;116(23):4948-57. doi: 10.1182/blood-2009-10-247361. Epub 2010 Aug 30.

21.

Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia.

Dedhia PH, Keeshan K, Uljon S, Xu L, Vega ME, Shestova O, Zaks-Zilberman M, Romany C, Blacklow SC, Pear WS.

Blood. 2010 Aug 26;116(8):1321-8. doi: 10.1182/blood-2009-07-229450. Epub 2010 Apr 21.

22.

Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A.

Yashiro-Ohtani Y, He Y, Ohtani T, Jones ME, Shestova O, Xu L, Fang TC, Chiang MY, Intlekofer AM, Blacklow SC, Zhuang Y, Pear WS.

Genes Dev. 2009 Jul 15;23(14):1665-76. doi: 10.1101/gad.1793709.

23.

Menin regulates the function of hematopoietic stem cells and lymphoid progenitors.

Maillard I, Chen YX, Friedman A, Yang Y, Tubbs AT, Shestova O, Pear WS, Hua X.

Blood. 2009 Feb 19;113(8):1661-9. doi: 10.1182/blood-2009-01-135012.

24.

Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.

Chiang MY, Xu L, Shestova O, Histen G, L'heureux S, Romany C, Childs ME, Gimotty PA, Aster JC, Pear WS.

J Clin Invest. 2008 Sep;118(9):3181-94. doi: 10.1172/JCI35090.

25.

Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells.

Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE, Aster JC, Bhandoola A, Radtke F, Pear WS.

Cell Stem Cell. 2008 Apr 10;2(4):356-66. doi: 10.1016/j.stem.2008.02.011.

26.

Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia.

Keeshan K, Shestova O, Ussin L, Pear WS.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):119-21. Epub 2007 Nov 7.

PMID:
17988908
27.

Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.

Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, Rodriguez CG, Maillard I, Tobias JW, Valk P, Carroll M, Aster JC, Delwel R, Pear WS.

Cancer Cell. 2006 Nov;10(5):401-11.

28.

The requirement for Notch signaling at the beta-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor.

Maillard I, Tu L, Sambandam A, Yashiro-Ohtani Y, Millholland J, Keeshan K, Shestova O, Xu L, Bhandoola A, Pear WS.

J Exp Med. 2006 Oct 2;203(10):2239-45. Epub 2006 Sep 11.

29.

Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1.

Chiang MY, Xu ML, Histen G, Shestova O, Roy M, Nam Y, Blacklow SC, Sacks DB, Pear WS, Aster JC.

Mol Cell Biol. 2006 Aug;26(16):6261-71.

30.

Notch-dependent T-lineage commitment occurs at extrathymic sites following bone marrow transplantation.

Maillard I, Schwarz BA, Sambandam A, Fang T, Shestova O, Xu L, Bhandoola A, Pear WS.

Blood. 2006 May 1;107(9):3511-9. Epub 2006 Jan 5.

31.

Notch signaling is an important regulator of type 2 immunity.

Tu L, Fang TC, Artis D, Shestova O, Pross SE, Maillard I, Pear WS.

J Exp Med. 2005 Oct 17;202(8):1037-42.

32.

Purification and Characterization of Apoptotic Factors from Human Milk.

Semenov DV, Kuligina EV, Shestova OE, Potapenko MO, Romannikova IV, Richter VA.

ScientificWorldJournal. 2001 Oct 17;1:56. doi: 10.1100/tsw.2001.172. eCollection 2001. No abstract available.

33.

Human anti-DNA secretory immunglobulins A possess endonuclease activity and they are able to cause the destruction of nuclear chromatin in vitro.

Kit Y, Mitrofanova EE, Shestova OE, Kuligina EV, Romannikova IV, Richter VA.

Ukr Biokhim Zh (1999). 2000 May-Jun;72(3):73-6.

PMID:
11200479
34.

[Transport of oligonucleotides-cell surface proteins complexes into cell nucleus].

Shestova OE, Andreeva AIu, Vlasov VV, Iakubov LA.

Dokl Akad Nauk. 1999 Sep;368(2):264-7. Russian. No abstract available.

PMID:
10546059
35.

[Participation of specific cell surface proteins in the transport of nucleic acids into cells].

Iakubov LA, Shestova OE, Andreeva AIu, Vlasov VV.

Dokl Akad Nauk. 1998 Aug;361(4):550-3. Russian. No abstract available.

PMID:
9777304
36.

[Oligonucleotides absorbed by a cell quickly accumulate in the nucleus].

Vlasov VV, Nechaeva MV, Baĭborodin SI, Shestova OE, Safronov IV, Koshkin AA, Iakubov LA.

Dokl Akad Nauk. 1995 Nov;345(1):123-6. Russian. No abstract available.

PMID:
8580859
37.

[Possible relationship between the cytologic characteristics of mouse leukemia P-388 cells and their sensitivity to rubomycin].

Shestova OL, Litinskaia LL, Diagileva OA, Kotel'nikov VM, Pogorelov VM, Kozinets GI.

Gematol Transfuziol. 1993 Sep-Oct;38(8):15-8. Russian.

PMID:
8307297
38.

[Seasonal changes in lysosomal pH of peripheral blood cells of healthy subjects].

Kozinets GI, Shestova OL, Litinskaia LL, Ogloblina TA, Kotel'nikov VM.

Biull Eksp Biol Med. 1990 Dec;110(12):655-7. Russian.

PMID:
1707320
39.

[Role of intracellular pH in the development of resistance of leukemic cells to antineoplastic drugs].

Shestova OL, Ogloblina TA, Litinskaia LL.

Eksp Onkol. 1990;12(3):61-2. Russian.

PMID:
2344828
40.

[Changes in the pH of leukocyte granules during the storage of preserved donor blood].

Shestova OL, Kotel'nikov VM, Kozinets GI.

Gematol Transfuziol. 1989 Dec;34(12):28-32. Russian.

PMID:
2628150

Supplemental Content

Loading ...
Support Center